Breast cancer tumor vaccine being studied at Stony Brook Medicine
Newsday • • health
Key Points:
- Christine Amitrano, diagnosed with HER2-positive breast cancer at 35, is participating in the FLAMINGO-01 Phase III clinical trial testing an experimental vaccine aimed at reducing cancer recurrence and metastasis.
- The trial, involving 160 sites worldwide including Stony Brook Cancer Center, administers six initial vaccine injections over six months followed by five booster shots to prevent metastatic breast cancer.
- Early detection played a crucial role in Amitrano’s treatment, as her mother urged her to get a mammogram before the usual recommended age of 40, leading to timely diagnosis and aggressive treatment.
- Amitrano’s cancer experience inspired her career change from physical education teacher to MRI X-ray technician, emphasizing the importance of early diagnosis and patient involvement in clinical trials.
- Medical professionals at Stony Brook encourage participation in clinical trials, highlighting rigorous monitoring and the crucial role such studies play in advancing breast cancer treatments and improving patient outcomes.
